SEC Comment Letter 0000000000-23-009912 to Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc.
Date: Sept. 7, 2023 · CIK: 0001819133 · Accession: 0000000000-23-009912
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274298
Letter
United States securities and exchange commission logo September 7, 2023 Barbara Weber, M.D. President and Chief Executive Officer Tango Therapeutics, Inc. 201 Brookline Avenue, Suite 901 Boston, MA 02215 Re:Tango Therapeutics, Inc. Registration Statement on Form S-3 Filed September 1, 2023 File No. 333-274298 Dear Barbara Weber: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: William D. Collins, Esq.
Show Raw Text
United States securities and exchange commission logo
September 7, 2023
Barbara Weber, M.D.
President and Chief Executive Officer
Tango Therapeutics, Inc.
201 Brookline Avenue, Suite 901
Boston, MA 02215
Re:Tango Therapeutics, Inc.
Registration Statement on Form S-3
Filed September 1, 2023
File No. 333-274298
Dear Barbara Weber:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: William D. Collins, Esq.